The only upside is to average down.
The downside of course,is risking more money.
January may help with reimbursement coding and trial updates, but unless there is another IP agreement announcement, this stock is destined to meander until the CLIA trial is completed and FDA approved.
Management continue to be a one-man-band.
Thankfully we are funded for the next 12 months.
Add to My Watchlist
What is My Watchlist?
